Manager TitleAgeSince
Chief Executive Officer 46 23/04/1997
Director of Finance/CFO 49 01/01/2020
Investor Relations Contact 50 -
Director TitleAgeSince
Director/Board Member 43 30/09/2019
Date Insider Type Main position Quantity % Market Cap.
07/12/21Buy

Founder

100,000 0.2488%
07/12/21Buy

Director

50,000 0.1244%
06/12/21Buy

Founder

150,000 0.3731%
Change 5-day change 1-year change 3-year change Capi.($)
+35.00%+17.19% - - 21.26M
+1.30%-0.54%+60.77%+46.13% 133B
-0.59%-0.95%+8.12%+37.97% 90.2B
+0.83%+0.33%+1.50%+69.94% 27.41B
-0.29%-3.84%+23.41%+47.87% 22.96B
+0.61%+0.33%-18.94%-27.68% 19.9B
-1.22%+0.26%+16.22%+147.88% 17.59B
+2.48%+0.76%+8.17%+14.97% 15.5B
+1.45%-0.90%+63.31%+125.87% 14.95B
+0.22%+2.02%-9.36%-4.92% 12.75B
Average +3.98%-0.35%+17.02%+50.89% 39.35B
Weighted average by Cap. +0.54%-0.60%+28.94%+47.08%
Logo Novamind Inc.
Novamind Inc., formerly Hinterland Metals Inc., is a Canada-based mental health company. The Company enables safe access to psychedelic medicine through a network of psychiatry clinics, and clinical research sites. It provides mental health services through its subsidiary, Cedar Psychiatry and provides clinical trial services through its other subsidiary, Cedar Clinical Research (CCR). Cedar Psychiatry offers psychotherapy, psychiatric medication management, transcranial magnetic stimulation (TMS) and ketamine-assisted psychotherapy. CCR specializes in hosting Phase I to Phase IV clinical trials and research focused on emerging treatment options in neuropsychiatry on behalf of third-party sponsors. CCR operates a research center in Springville, Utah, which provides select contract research organization (CRO) services for pharmaceutical companies. CCR is also developing psychedelic-assisted psychotherapy treatment protocols to provide patients with evidence-based therapies.
Employees
-
  1. Stock Market
  2. Stocks
  3. NVMDF Stock